139 related articles for article (PubMed ID: 20797983)
1. Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial.
Zhang M; Tsiatis AA; Davidian M; Pieper KS; Mahaffey KW
Biostatistics; 2011 Apr; 12(2):258-69. PubMed ID: 20797983
[TBL] [Abstract][Full Text] [Related]
2. The impact of postrandomization crossover of therapy in acute coronary syndromes care.
Mahaffey KW; Pieper KS; Lokhnygina Y; Califf RM; Antman EM; Kleiman NS; Goodman SG; White HD; Rao SV; Hochman JS; Cohen M; Col JJ; Roe MT; Ferguson JJ;
Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):211-9. PubMed ID: 21304094
[TBL] [Abstract][Full Text] [Related]
3. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
Mahaffey KW; Ferguson JJ
Am Heart J; 2005 Apr; 149(4 Suppl):S81-90. PubMed ID: 16124952
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
[TBL] [Abstract][Full Text] [Related]
5. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
Ferguson JJ; Califf RM; Antman EM; Cohen M; Grines CL; Goodman S; Kereiakes DJ; Langer A; Mahaffey KW; Nessel CC; Armstrong PW; Avezum A; Aylward P; Becker RC; Biasucci L; Borzak S; Col J; Frey MJ; Fry E; Gulba DC; Guneri S; Gurfinkel E; Harrington R; Hochman JS; Kleiman NS; Leon MB; Lopez-Sendon JL; Pepine CJ; Ruzyllo W; Steinhubl SR; Teirstein PS; Toro-Figueroa L; White H;
JAMA; 2004 Jul; 292(1):45-54. PubMed ID: 15238590
[TBL] [Abstract][Full Text] [Related]
6. Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
Mahaffey KW; Tonev ST; Spinler SA; Levine GN; Gallo R; Ducas J; Goodman SG; Antman EM; Becker RC; Langer A; White HD; Aylward PE; Col JJ; Ferguson JJ; Califf RM;
Int J Cardiol; 2010 Mar; 139(2):123-33. PubMed ID: 19012977
[TBL] [Abstract][Full Text] [Related]
7. The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
Becker RC
Am Heart J; 2005 Aug; 150(2):189-92. PubMed ID: 16086916
[No Abstract] [Full Text] [Related]
8. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW
J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342
[TBL] [Abstract][Full Text] [Related]
9. Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.
Petersen JL; Mahaffey KW; Becker RC; Goodman SG; Kleiman NS; Marian AJ; Stone GW; Lansky AJ; Lincoff AM; Hazen SL; Nessel CC; Toro-Figueroa L; Tate L; Reist CJ; Cohen M; Califf RM; Ferguson JJ;
Am Heart J; 2004 Aug; 148(2):269-76. PubMed ID: 15308996
[TBL] [Abstract][Full Text] [Related]
10. Enoxaparin versus heparin: the SYNERGY trial from an emergency medicine perspective.
Rokos IC
Drugs; 2005; 65(10):1313-6. PubMed ID: 15977965
[TBL] [Abstract][Full Text] [Related]
11. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.
Goodman SG; Fitchett D; Armstrong PW; Tan M; Langer A;
Circulation; 2003 Jan; 107(2):238-44. PubMed ID: 12538422
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of anticoagulation in acute coronary syndromes.
Latour-Pérez J; de-Miguel-Balsa E
Pharmacoeconomics; 2012 Apr; 30(4):303-21. PubMed ID: 22409291
[TBL] [Abstract][Full Text] [Related]
13. Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial.
Lopes RD; Alexander KP; Marcucci G; White HD; Spinler S; Col J; Aylward PE; Califf RM; Mahaffey KW
Eur Heart J; 2008 Aug; 29(15):1827-33. PubMed ID: 18519426
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
White HD; Chew DP; Hoekstra JW; Miller CD; Pollack CV; Feit F; Lincoff AM; Bertrand M; Pocock S; Ware J; Ohman EM; Mehran R; Stone GW
J Am Coll Cardiol; 2008 May; 51(18):1734-41. PubMed ID: 18452778
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM;
JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591
[TBL] [Abstract][Full Text] [Related]
16. Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial).
Lansky AJ; Mehran R; Cristea E; Parise H; Feit F; Ohman EM; White HD; Alexander KP; Bertrand ME; Desmet W; Hamon M; Stone GW
Am J Cardiol; 2009 May; 103(9):1196-203. PubMed ID: 19406258
[TBL] [Abstract][Full Text] [Related]
17. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale.
Stone GW; Bertrand M; Colombo A; Dangas G; Farkouh ME; Feit F; Lansky AJ; Lincoff AM; Mehran R; Moses JW; Ohman M; White HD
Am Heart J; 2004 Nov; 148(5):764-75. PubMed ID: 15523305
[TBL] [Abstract][Full Text] [Related]
18. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview.
Petersen JL; Mahaffey KW; Hasselblad V; Antman EM; Cohen M; Goodman SG; Langer A; Blazing MA; Le-Moigne-Amrani A; de Lemos JA; Nessel CC; Harrington RA; Ferguson JJ; Braunwald E; Califf RM
JAMA; 2004 Jul; 292(1):89-96. PubMed ID: 15238596
[TBL] [Abstract][Full Text] [Related]
20. Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial.
Goodman S
Am Heart J; 2005 Apr; 149(4 Suppl):S73-80. PubMed ID: 16124951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
